Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame

References

• Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2013-2018). 2013
   Google Scholar
• Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin’s strains) in persons after naturally and experimentally acquired immunity. Acta Virol 1961;5:265-73
   Web of Science ®Google Scholar
• Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 2009;183(11):6883-92
   PubMed Web of Science ®Google Scholar
• Hanlon P, Hanlon L, Marsh V, et al. Serological comparisons of approaches to polio vaccination in the Gambia. Lancet 1987;1:800-1
   PubMed Web of Science ®Google Scholar
• Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993;341:1545-50
   PubMed Web of Science ®Google Scholar
• Stickle G. Observed and expected poliomyelitis in the United States. 1958-1961. Am J Public Health Nations Health 1964;54:1222-9
   PubMed Web of Science ®Google Scholar
• Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010;376:1682-8
   PubMed Web of Science ®Google Scholar
• Cochi SL, Linkins RW. The final phase of polio eradication: new vaccines and complex choices. J Infect Dis 2012;205:169-71
   PubMed Web of Science ®Google Scholar
• Rationale and timelines for OPV withdrawal. WHO. Available from: www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/planning/en/ [Last accessed 5 March 2015]
   Google Scholar
• Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014;210(Suppl 1):S380-9
   PubMed Web of Science ®Google Scholar
• Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010;172:1213-29
   PubMed Web of Science ®Google Scholar
• Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014;210(Suppl 1):S283-93
   PubMed Web of Science ®Google Scholar
• Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010;362:2360-9
   PubMed Web of Science ®Google Scholar
• Mangal TD, Aylward RB, Mwanza M, et al. Key issues in the persistence of poliomyelitis in Nigeria: a case-control study. Lancet Glob Health 2014;2:e90-7
   PubMed Web of Science ®Google Scholar
• Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014;345:922-5
   PubMed Web of Science ®Google Scholar
• John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014;384:1505-12
   PubMed Web of Science ®Google Scholar
• WHO. Manual of laboratory methods for testing of vaccines used in the WHO Expanded Programme on Immunization. WHO/VSQ/9704; 1997
   Google Scholar
• Hammon WM, Coriell LL, Ludwig EH, et al. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 5. Reanalysis of results based on laboratory-confirmed cases. J Am Med Assoc 1954;156:21-7
   PubMed Web of Science ®Google Scholar
• Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg 1962;76:173-95
   PubMed Web of Science ®Google Scholar
• Zhaori G, Sun M, Faden HS, Ogra PL. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 1989;159:1018-24
   PubMed Web of Science ®Google Scholar
• Herremans TM, Reimerink JH, Buisman AM, et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999;162:5011-18
   PubMed Web of Science ®Google Scholar
• Ogra PL, Karzon DT, Righthand F, MacGillivray M. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 1968;279:893-900
   PubMed Web of Science ®Google Scholar
• Faden H, Modlin JF, Thoms ML, et al. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990;162:1291-7
   PubMed Web of Science ®Google Scholar
• Ogra PL, Karzon DT. Formation and function of poliovirus antibody in different tissues. Prog Med Virol 1971;13:156-93
   Google Scholar
• Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8:e1002599
   PubMed Web of Science ®Google Scholar
• Grassly NC, Jafari H, Bahl S, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis 2012;205:1554-61
   PubMed Web of Science ®Google Scholar
• Herremans T, Kimman TG, Conyn-Van Spaendonck MA, et al. Immunoglobulin A as a serological marker for the (silent) circulation of poliovirus in an inactivated poliovirus-vaccinated population. Clin Infect Dis 2002;34:1067-75
   PubMed Web of Science ®Google Scholar
• Davis DC, Lipson MJ, Carver DH, et al. The degree and duration of poliomyelitis virus excretion among vaccinated household contacts of clinical cases of poliomyelitis. Pediatrics 1958;22:33-40
   PubMed Web of Science ®Google Scholar
• Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007;356:1536-44
   PubMed Web of Science ®Google Scholar
• Enders-Ruckle G, Siegert R. [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)]. Dtsch Med Wochenschr 1961;86:1999-2008
   PubMed Web of Science ®Google Scholar
• Henry JL, Jaikaran ES, Davies JR, et al. A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond) 1966;64:105-20
   PubMedGoogle Scholar
• Glezen WP, McCollough RH, Lamb GA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol 1969;90:146-56
   PubMed Web of Science ®Google Scholar
• Laassri M, Lottenbach K, Belshe R, et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 2005;192:2092-8
   PubMed Web of Science ®Google Scholar
• Wehrle PF, Carbonaro O, Day PA, et al. Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. Pediatrics 1961;27:762-4
   PubMed Web of Science ®Google Scholar
• Dick GW, Dane DS, McAlister J, et al. Vaccination against poliomyelitis with live virus vaccines. 7. Effect of previous Salk vaccination on virus excretion. Br Med J 1961;2:266-9
   PubMed Web of Science ®Google Scholar
• Glezen WP, Lamb GA, Belden EA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 1966;83:224-37
   PubMed Web of Science ®Google Scholar
• Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis 1984;6(Suppl 2):S361-8
   PubMedGoogle Scholar
• Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996;14:735-46
   PubMed Web of Science ®Google Scholar
• Anis E, Kopel E, Singer SR, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill 2013;18(38):pii/20651
   Google Scholar
• Kopel E, Kaliner E, Grotto I. Lessons from a public health emergency – importation of wild poliovirus to Israel. N Engl J Med 2014;371:981-3
   PubMed Web of Science ®Google Scholar
• Parent du Chatelet I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003;21:1710-18
   PubMed Web of Science ®Google Scholar
• WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Bull World Health Organ 1996;74:253-68
   PubMed Web of Science ®Google Scholar
• Sutter RW, Suleiman AJ, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000;343:767-73
   PubMed Web of Science ®Google Scholar
• Modlin JF, Halsey NA, Thoms ML, et al. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine – live attenuated oral poliovirus vaccine immunization schedules. J Infect Dis 1997;175:S228-34
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011;239:125-48
   PubMed Web of Science ®Google Scholar
• Krieg C, Maier R, Meyerhans A. Gut-homing (alpha(4)beta(7)(+)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. J Gen Virol 2004;85:1571-9
   PubMed Web of Science ®Google Scholar
• Herremans MM, van Loon AM, Reimerink JH, et al. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands. Clin Diagn Lab Immunol 1997;4:499-503
   PubMedGoogle Scholar
• Estivariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013;3:309-15
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013;368:416-24
   PubMed Web of Science ®Google Scholar
• Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014;210(Suppl 1):S439-46
   PubMed Web of Science ®Google Scholar
• Anand A, Pallansch MA, Estivariz CF, et al. Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys. J Infect Dis 2014;210(Suppl 1):S465-74
   PubMed Web of Science ®Google Scholar
• Wassilak S, Pate MA, Wannemuehler K, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis 2011;203:898-909
   PubMed Web of Science ®Google Scholar
• Sharif S, Abbasi BH, Khurshid A, et al. Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of Southern Afghanistan during June. 2009-February 2011. PLoS One 2014;9:e88442
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Melnick JL. Heterotypic antibody response after feeding of monovalent attenuated live poliovaccine. N Engl J Med 1962;267:1228-30
   PubMed Web of Science ®Google Scholar
• Hovi T, Roivainen M. Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus. J Clin Microbiol 1993;31(5):1083-7
   PubMed Web of Science ®Google Scholar
• Sabin AB. Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus. J Exp Med 1952;96:99-106
   PubMed Web of Science ®Google Scholar
• Implementation of inactivated polio vaccine (IPV) campaigns. Global Polio Eradication Initiative. Available from: www.polioeradication.org/Portals/0/Document/Aboutus/Governance/IMB/11IMBMeeting/2.5_11IMB.pdf [Last accessed 05 March 2015]
   Google Scholar
• Asghar H, Diop OM, Weldegebriel G, et al. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. J Infect Dis 2014;210(Suppl 1):S294-303
   PubMed Web of Science ®Google Scholar
• Joint GPEI-GAVI statement on the availability and price of inactivated polio vaccine. UNICEF. Available from: www.unicef.org/media/media_72738.html [Last accessed 19 March 2015]
   Google Scholar
• Vaccine price data. UNICEF. Available from: www.unicef.org/supply/index_57476.html [Last accessed 19 March 2015]
   Google Scholar
• Samuel BU, Cherian T, Sridharan G, et al. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991;338:343-4
   PubMed Web of Science ®Google Scholar
• Nirmal S, Cherian T, Samuel BU, et al. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998;16:928-31
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010;362:2351-9
   PubMed Web of Science ®Google Scholar
• Estivariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012;12:128-35
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Mach O, et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine 2015;33:307-13
   PubMed Web of Science ®Google Scholar
• Bakker WA, Thomassen YE, van’t Oever AG, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011;29:7188-96
   PubMed Web of Science ®Google Scholar
• Verdijk P, Rots NY, van Oijen MG, et al. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 2014;32:4938-44
   PubMed Web of Science ®Google Scholar
• Steil BP, Jorquera P, Westdijk J, et al. A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine 2014;32:448-63
   Web of Science ®Google Scholar
• Macadam AJ, Ferguson G, Stone DM, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 2006;80:8653-63
   PubMed Web of Science ®Google Scholar
• Mahmood K, Pelkowski S, Atherly D, et al. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother 2013;9:1894-902
   PubMed Web of Science ®Google Scholar
• Sawyer LA, McInnis J, Patel A, et al. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine 1994;12:851-6
   PubMed Web of Science ®Google Scholar
• Status update on country planning for IPV introduction. WHO. Available from: www.who.int/entity/immunization/diseases/poliomyelitis/endgame_objective2/IPVmap_2015_May.pptx?ua=1 [Last accessed 14 May 2015]
   Google Scholar